Exciting breakthroughs like these are happening more frequently because individuals are dropping weight through GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, which reduce hunger cravings. Approximately 1.4 million residents in the United Kingdom obtained these from private drugstores during the period up to April, based on data from Iqvia, a provider of clinical studies, even though the latest updates indicate an even larger total. The research firm Rand reports that roughly 12 percent of people in the United States have tried them.
This article explores the growing prevalence of weight-loss injections such as Ozempic in everyday life. It highlights rising adoption rates in the UK and US, potentially transforming workplace dynamics. Key statistics from research providers underscore the trend.
Shotlee··Updated Jan 27, 2026·1 min read
Original source: Financial Post
View original article →#Ozempic#workplace#weight-loss drugs#GLP-1#UK usage#US statistics
